Yoshihiko Taniguchi - Concepedia

Author

Yoshihiko Taniguchi

NHO Kinki Chuo Chest Medical Center ORCID

Also Known As

Y Taniguchi, Y. Taniguchi, YOSHIHIKO TANIGUCHI, Yoshihiko TANIGUCHI, Yoshihiko Taniguchi, Yuichi Adachi

163

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

NHO Kinki Chuo Chest Medical Center Osaka International Cancer Institute Osaka Prefectural Medical Center Hiroshima University National Hospital Organization

About

Yoshihiko Taniguchi is an author at NHO Kinki Chuo Chest Medical Center specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	485
2	Health Sciences	3	3	69
3	Cell Biology	1	1	13
4	Cellular Physiology	1	1	13
5	Gastroenterology	1	1	25

Yoshihiko Taniguchi

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Pretreatment advanced lung cancer inflammation index (<scp>ALI</scp>) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya, Cancer Medicine	2017	121
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer Rong Wang, Tadaaki Yamada, Kenji Kita, Nature Communications	2020	112
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial Motohiro Tamiya, Akihiro Tamiya, Takako Inoue, PLoS ONE	2018	105
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab Yoshihiko Taniguchi, Akihiro Tamiya, Syun-Ichi Isa, Anticancer Research	2017	67
Analysis of Early Death in Japanese Patients With Advanced Non–small-cell Lung Cancer Treated With Nivolumab Takako Inoue, Motohiro Tamiya, Akihiro Tamiya, Clinical Lung Cancer MedicineCancer ManagementPathologyImmune Checkpoint InhibitorCancer Treatment	2017	66
Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status Yuichi Adachi, Akihiro Tamiya, Yoshihiko Taniguchi, Cancer Medicine	2019	57
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON) Go Saito, Yuko Oya, Yoshihiko Taniguchi, Lung Cancer Durvalumab Consolidation TherapyMedicineMetronomic TherapyReal-world SurveyBronchial Neoplasm	2021	53
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001) Motohiro Tamiya, Akihiro Tamiya, Kazutaka Hosoya, Investigational New Drugs First-line TherapyMedicineLeast 50PathologyImmune Checkpoint Inhibitor	2019	52
Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya, Anticancer Research	2018	51
Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab Yoshihiko Taniguchi, Akihiro Tamiya, S.-I. Isa, Annals of Oncology Non-small-cell Lung CancerMedicinePredictive FactorsCancer ManagementBronchial Neoplasm	2017	45

Page 1